Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells
- 1 November 1988
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 18 (11) , 1791-1796
- https://doi.org/10.1002/eji.1830181121
Abstract
We have analyzed the effect mediated by prostaglandin E2 (PGE2) and different reagents that increase intracellular cAMP on the expression of the p55 subunit (CD25) of interleukin 2 receptors (IL2R), on the levels of CD25‐specific mRNA and on the expression of high affinity IL 2R. In purified T cells, activated either by an anti‐CD3 monoclonal antibody or phytohemagglutinin, the addition of PGE2 (10−6 M), forskolin (5 × 10−5 M), cholera toxin (0.2 μg/ml) or dibutyryl cAMP (dBcAMP) (10−4 M) decreased the cell surface expression of IL 2R by reducing (40%‐78% inhibition) the proportions of CD25+ cells as well as the expression of high affinity IL2R, detectable after 24 h. Furthermore, it was observed that PGE2 reduced the concentration of IL2R‐specific mRNA after a 6‐h period of activation, indicating that its regulatory activity takes place at a pretranslational level. The addition of exogenous recombinant IL2 only partially reversed the inhibition, thus suggesting that PGE2 and increased intracellular concentration of cAMP directly interfered with CD25 expression and that their effect could not be merely attributed to a lack of IL2 dependent positive feedback. Cells cultured under the same conditions in the presence of phorbol myristate acetate, that activates protein kinase C, were refractory to the CAMP‐mediated regulation. Finally, we demonstrate that both PGE2 and dBcAMP inhibit the generation of inositol metabolites after T cell activation, thus indicating that these reagents interfere with early signal transduction mechanisms which precede the synthesis of IL2R.This publication has 27 references indexed in Scilit:
- CD2 is involved in regulating cyclic AMP levels in T cellsEuropean Journal of Immunology, 1988
- Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor.The Journal of Experimental Medicine, 1987
- Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate.Journal of Clinical Investigation, 1987
- Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.The Journal of Experimental Medicine, 1987
- Novel Interleukin-2 Receptor Subunit Detected by Cross-Linking Under High-Affinity ConditionsScience, 1986
- Selection and characterization of monoclonal antibodies to the idiotype‐like structure of an interleukin‐2‐producing human leukemia t‐cell lineInternational Journal of Cancer, 1985
- Prostaglandin E inhibits the production of human interleukin 2.The Journal of Experimental Medicine, 1982
- Cyclic adenosine monophosphate response to prostaglandin E2 on subpopulations of human lymphocytes.The Journal of Experimental Medicine, 1979
- Phosphatidylinositol-specific phospholipase-C of platelets: Association with 1,2-diacylglycerol-kinase and inhibition by cyclic-AMPBiochemical and Biophysical Research Communications, 1979
- Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell.The Journal of Experimental Medicine, 1977